Company Profile

Admunex Therapeutics Inc
Profile last edited on: 7/29/19      CAGE:       UEI:

Business Identifier: Unique process of targeting and destroying the T-cells that cause autoimmune diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

140 South Wolfe Road
Sunnyvale, CA 94086
   (408) 245-0003
Location: Single
Congr. District: 17
County: Santa Clara

Public Profile

Now located in CA, Admunex is a “spin off” company from the Higuchi Biosciences Center at the University of Kansas that is developing novel platform technologies to treat autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company’s primary technology involves a unique process of targeting and destroying the T-cells that cause autoimmune diseases. Admunex was founded to commercialize new medicines for the treatment of autoimmune diseases. Admunex's products are derived from patented inventions discovered in Professor Teruna Siahaan's research laboratory in the Pharmaceutical Chemistry Department at the University of Kansas (KU). Basic research to understand the cellular communication processes conducted in Professor Siahaan's research group lead to the discoveries and patented inventions. As a result of this new understanding of the cellular communication processes, Admunex scientists are able to exploit nature's cell biology to deliver existing and new therapeutic agents to the diseased cell. Rheumatoid arthritis (RA) and multiple sclerosis (MS) are the initial clinical targets for Admunex's cell-specific targeted drug delivery technolo

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2004 1 NIH $100,000
Project Title: Lymphocyte Targeting by Peptide-Drug Conjugates

Key People / Management

  Tom Malefyt -- President

  Leo C Gu

Company News

There are no news available.